Product Name: Human ACVR2B Antibody (Bimagrumab, Research Use)
Catalog Number: NBR-0095
Target Name: ACVR2B
Trade Name: Bimagrumab
Antibody Drug Description: Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013, it was announced that bimagrumab had received a breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by the US Food and Drug Administration. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: ACVR2B
Synonyms: ActR-IIB
Target Description: Transmembrane serine/threonine kinase activin type-2 receptor forming an activin receptor complex with activin type-1 serine/threonine kinase receptors (ACVR1, ACVR1B or ACVR1c).
Ensembl:  ENSG00000114739
Uniprot: Q13705